Food Microbiology Testing Market 2020 is Booming Worldwide

Germany English News | April 08, 2020

Food Microbiology Testing Market report provides an in-depth analysis of the overall market over a period from 2020-2026. The Food Microbiology Testing Market report also provides the market impact and new opportunities created due to the COVID19 catastrophe. The Food Microbiology Testing Market has been segmented based on different types and application. In order to provide a holistic view of the market current and future market, demand has been included in the report. The Food Microbiology Testing market report covers major market players like 3M, Neogen, Eurofins Scientific, Bio-Rad, Thermo Fisher Scientific, Michigan Testing, Certified Laboratories, Accugen Labs, Inc. Performance Analysis of Food Microbiology Testing Industry 2020 Highlighting Recent Market Growth, Trends and Development 2026 Forecast Report.

Spotlight

Lung fibrosis is a serious condition that thickens tissues in the lungs and makes it hard to breathe. It can be caused by a variety of environmental factors, including exposure to coal or grain dust. New work has shown that it may be possible to prevent the disease with a drug that can block structural changes to collagen. It has been suggested that it is not the amount, but rather the structure of collagen that can lead to lung fibrosis. This research, reported in eLife, has also revealed how drugs can protect against those changes.

Spotlight

Lung fibrosis is a serious condition that thickens tissues in the lungs and makes it hard to breathe. It can be caused by a variety of environmental factors, including exposure to coal or grain dust. New work has shown that it may be possible to prevent the disease with a drug that can block structural changes to collagen. It has been suggested that it is not the amount, but rather the structure of collagen that can lead to lung fibrosis. This research, reported in eLife, has also revealed how drugs can protect against those changes.

Related News

INDUSTRY OUTLOOK

Expanding Diagnostics Business: SCHOTT Signs Agreement to Acquire Applied Microarrays Inc.

Applied Microarrays Inc. | September 30, 2021

SCHOTT MINIFAB, a subsidiary of SCHOTT that develops and manufactures microfluidic devices for point-of-care and life sciences consumables, has had a long-standing close customer relationship with Applied Microarrays Inc. (AMI). Together, they develop biotech substrates for diagnostics applications. The expertise of AMI will further strengthen SCHOTT’s ability to offer a single-source contract manufacturing solution. The deal is expected to close in early October. Through this acquisition, SCHOTT MINIFAB significantly expands its biosensor printing capabilities. This is of particular importance as demand is growing for the manufacturing of point-of-care microarray consumables, especially in applications such as infectious disease detection. “We pride ourselves on being an end-to-end partner for the global diagnostics industry. Our expansive offering allows us to provide an integrated single-source collection of value-intensive services and products. With the added bioscience knowledge of AMI, we become an even stronger partner, enhancing our capability in surface modification, functionalization and deposition for both glass and polymer products.” - Greg Wolters, Head of SCHOTT MINIFAB. AMI will soon be moving to a larger facility in the Phoenix, Arizona area. Its new location will greatly increase SCHOTT’s manufacturing footprint in the United States to serve its global customer base. Pioneering – responsibly – together These attributes characterize SCHOTT as a manufacturer of high-tech materials based on specialty glass. Founder Otto Schott is considered its inventor and became the pioneer of an entire industry. Always opening up new markets and applications with a pioneering spirit and passion – this is what has driven the #glasslovers at SCHOTT for more than 130 years. Represented in 34 countries, the company is a highly skilled partner for high-tech industries: Healthcare, Home Appliances & Living, Consumer Electronics, Semiconductors & Datacom, Optics, Industry & Energy, Automotive, Astronomy & Aerospace. In the fiscal year 2020, its 16,500 employees generated sales of 2.24 billion euros. With the best teams, supported by the best digital tools, the group intends to continue to grow. SCHOTT AG is owned by the Carl Zeiss Foundation, one of the oldest foundations in Germany. It uses the Group's dividends to promote science. As a foundation company, SCHOTT has anchored responsibility for employees, society and the environment deeply in its DNA. The goal is to become a climate-neutral company by 2030. About Applied Microarrays (AMI) AMI is a company headquartered in Tempe, AZ, which designs, optimizes and manufactures DNA and protein biosensors, and other microarrays on glass, plastic and semiconductors. AMI operates under ISO 9001 and ISO 13485 certification. Since acquiring GE Healthcare’s microarray business in 2007, AMI has evolved to become a full service provider for RUO and Dx devices.

Read More

AI

BioMarin and Deep Genomics to Collaborate on Advancing Programs Identified Using Artificial Intelligence

BioMarin | November 18, 2020

BioMarin Pharmaceutical Inc. and Deep Genomics declares that the organizations have gone into a preclinical collaboration that will use Deep Genomics' artificial intelligence drug discovery platform (The AI Workbench) to distinguish oligonucleotide drug applicants in four uncommon sickness signs with high neglected need. Deep Genomics will get an undisclosed forthright installment and is qualified to get improvement achievements as a piece of the coordinated effort. BioMarin will get an elite alternative to get Deep Genomics' privileges to each program for development and commercialization. The organizations didn't uncover financial terms. In the cooperation, Deep Genomics will utilize its AI Workbench to recognize and approve target components and lead competitors, and BioMarin will propel them into preclinical and clinical development. The AI Workbench empowers quick investigation of novel targetable components and restorative up-and-comers. It joins deep learning, automation, progressed biomedical information and huge measures of in vitro and in vivo information to precisely recognize targetable sub-atomic systems and guide the revelation and advancement of oligonucleotide treatments.

Read More

MEDICAL

MindMed Announces the start of the First Ever Clinical Trial Measuring and Evaluating MDMA and LSD

MindMed | January 21, 2021

MindMed, a main psychedelic medication biotech organization, reported today the beginning of the principal ever clinical preliminary estimating and assessing MDMA and LSD utilized in mix in the human body. The preliminary will be directed at the University Hospital Basel Liechti Lab, in Basel, Switzerland. If administered in combination with LSD, MDMA may expand positive abstract medication impacts, including positive state of mood and empathy, and lessen the negative feelings and nervousness that are sometimes associated with LSD - creating a general more good experience. MindMed is undertaking a Phase 1 clinical preliminary to assess if MDMA, when adjusted and utilized in combination with LSD, can help offset a portion of the known expected horrendous impacts of LSD that happen in treatment or clinical settings. MindMed is keen on arrangement how to adjust both MDMA and LSD in a strong manner to make better patient results, and grow further developed hallucinogenic helped treatments, as MindMed extends the two its R&D and commercial drug improvement pipeline. The examination is foreseen to take around one year to finish.

Read More